David J Panka

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
    Daniel C Cho
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 16:3628-38. 2010
  2. pmc An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood
    David J Panka
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Melanoma Res 20:401-7. 2010
  3. doi request reprint Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma
    David J Panka
    Beth Israel Deaconess Medical Center, Boston, Massachusetts
    Mol Cancer Ther 13:3210-8. 2014
  4. pmc Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells
    David J Panka
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Mol Cancer 12:17. 2013
  5. pmc Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma
    Qingjun Liu
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Mol Cancer 10:115. 2011
  6. ncbi request reprint GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Biol Chem 283:726-32. 2008
  7. doi request reprint Assaying for BRAF V600E in tissue and blood in melanoma
    David J Panka
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Methods Mol Biol 1102:117-36. 2014
  8. ncbi request reprint Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 12:2371s-2375s. 2006
  9. doi request reprint The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma
    David F McDermott
    Beth Israel Deaconess Medical Center, Dana Farber Harvard Cancer Center, Boston, Massachusetts
    Clin Cancer Res 21:561-8. 2015
  10. ncbi request reprint The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Cancer Res 66:1611-9. 2006

Detail Information

Publications10

  1. pmc The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
    Daniel C Cho
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 16:3628-38. 2010
    ....
  2. pmc An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood
    David J Panka
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Melanoma Res 20:401-7. 2010
    ..Using this protocol, mutant Braf can be detected in RNA from mixed populations with as few as 0.1% Braf(V600E) mutant cells...
  3. doi request reprint Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma
    David J Panka
    Beth Israel Deaconess Medical Center, Boston, Massachusetts
    Mol Cancer Ther 13:3210-8. 2014
    ..In summary, we have developed a highly sensitive and specific, blood-based assay to detect BRAF(V600) mutation in patients with melanoma...
  4. pmc Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells
    David J Panka
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Mol Cancer 12:17. 2013
    ..The studies reported herein were undertaken to determine if the angiostatic function of p53 could be exploited as an adjunct to VEGF-targeted therapy in the treatment of renal cell carcinoma (RCC)...
  5. pmc Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma
    Qingjun Liu
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Mol Cancer 10:115. 2011
    ..In this report, we describe the results of studies exploring the effects of GSK-3β on the cytotoxicity and antitumor activity of sorafenib combined with the HDM2 antagonist MI-319...
  6. ncbi request reprint GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Biol Chem 283:726-32. 2008
    ..These data provide a strong rationale for the use of GSK-3beta inhibitors as adjuncts to sorafenib treatment and suggest that preservation of Noxa may contribute to their efficacy...
  7. doi request reprint Assaying for BRAF V600E in tissue and blood in melanoma
    David J Panka
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Methods Mol Biol 1102:117-36. 2014
    ..Using this protocol, mutant BRAF can be detected in RNA from mixed populations with as few as 0.1 % BRAF(V600E) mutant containing cells...
  8. ncbi request reprint Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 12:2371s-2375s. 2006
    ....
  9. doi request reprint The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma
    David F McDermott
    Beth Israel Deaconess Medical Center, Dana Farber Harvard Cancer Center, Boston, Massachusetts
    Clin Cancer Res 21:561-8. 2015
    ..Retrospective studies suggested that clinical and pathologic features could predict for benefit. The Cytokine Working Group conducted this prospective trial to validate proposed predictive markers of response to HD IL2...
  10. ncbi request reprint The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Cancer Res 66:1611-9. 2006
    ..These data indicate that in sensitive cell lines, BAY 43-9006-induced apoptosis is independent of Bad dephosphorylation and caspase activation and largely mediated through the nuclear translocation of AIF...